Last updated: 2026-09-16 00:18:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Quantum Biopharma Ltd (QNTM) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $3.48, with a market capitalization of $134.40 and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.07 to $21.00. This page covers its latest market performance, valuation, price trends and company information.
$134.40 | |
$3.43 | |
$38.25 | |
$2.07 | |
$3.46 | |
101.06K | |
186.31K | |
-- | |
$21.00 | |
$2.07 | |
-- | |
-- |
Quantum Biopharma Ltd (QNTM) last closed at $3.46 as of 2026-09-15 23:55:00, unchanged from the previous close of $3.46.
During the latest regular trading session, QNTM traded between $2.07 and $38.25, with a volume of 101.06K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Quantum Biopharma Ltd (QNTM) moved from $2.95 to $3.48, representing a gain of 18.00% ($0.53).
The stock traded between $2.91 and $3.74 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 202.18 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 7.5%
QNTM is currently trading at $3.48, placing it 7.5% of the way from its 52-week low of $2.07 to its 52-week high of $21.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
| Employees | 7 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Quantum Biopharma Ltd (QNTM) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.